Potential use of CXCL12/CXCR4 and sonic hedgehog pathways as therapeutic targets in medulloblastoma

References

• Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas. A Pediatric Oncology Group Study. Cancer. 2002;94:552–560.
   Google Scholar
• Hershatter BW, Halperin EC, Cox EB. Medulloblastoma: the Duke University Medical Center experience. Int J Radiat Oncol Biol Phys. 1986;12:1771–1777.
   PubMed Web of Science ®Google Scholar
• PG F. Embryonal tumors. New York: Springer; 2004. (Gupta N BA, Haas-Kogan D, editor. Pediatric CNS Tumors).
   Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813–820.
   PubMed Web of Science ®Google Scholar
• ASCO ASoCO. Medulloblastoma – Childhood: Statistics. CancerNet Editorial Board. 2016.
   Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Gottardo NG, Hansford JR, McGlade JP, et al. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014;127:189–201.
   PubMed Web of Science ®Google Scholar
• Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007;6:1073–1085.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Taylor MD. Medulloblastoma: From Myth to Molecular. J Clin Oncol. 2017;35:2355–2363.
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004;5:209–218.
   PubMed Web of Science ®Google Scholar
• McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Development Biol. 2003;53:1–114.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhao R, Shi W, et al. Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases. Clinics. 2017;72:294–304.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Hielscher T, Dubuc A, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011;122:231–240.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31:306–310.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Mainprize TG, Rutka JT. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery. 2000;47:888–901.
   PubMed Web of Science ®Google Scholar
• Tran PB, Miller RJ. Chemokine receptors: signposts to brain development and disease. Nat Rev Neurosci. 2003;4:444–455.
   PubMed Web of Science ®Google Scholar
• de Haas AH, van Weering HR, de Jong EK, et al. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol. 2007;36:137–151.
   PubMed Web of Science ®Google Scholar
• Bagri A, Gurney T, He X, et al. The chemokine SDF1 regulates migration of dentate granule cells. Development. 2002;129:4249–4260.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu T, Zhang XC, et al. Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat Neurosci. 2002;5:719–720.
   PubMed Web of Science ®Google Scholar
• Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595–599.
   PubMed Web of Science ®Google Scholar
• Ohshima Y, Kubo T, Koyama R, et al. Regulation of axonal elongation and pathfinding from the entorhinal cortex to the dentate gyrus in the hippocampus by the chemokine stromal cell-derived factor 1 alpha. J Neurosci. 2008;28:8344–8353.
   PubMed Web of Science ®Google Scholar
• Sengupta R, Dubuc A, Ward S, et al. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res. 2012;72:122–132.
   PubMed Web of Science ®Google Scholar
• Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016;8. DOI: https://doi.org/10.3390/cancers8020022.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie Y, Oupický D. Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery. Curr Pharmacol Rep. 2016;2:1–10.
   PubMedGoogle Scholar
• Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287:795–801.
   PubMed Web of Science ®Google Scholar
• Chang DT, Lopez A, von Kessler DP, et al. Products, genetic linkage and limb patterning activity of a murine hedgehog gene. Development. 1994;120:3339–3353.
   PubMed Web of Science ®Google Scholar
• Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993;75:1417–1430.
   PubMed Web of Science ®Google Scholar
• Riddle RD, Johnson RL, Laufer E, et al. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell. 1993;75:1401–1416.
   PubMed Web of Science ®Google Scholar
• Roelink H, Augsburger A, Heemskerk J, et al. Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. Cell. 1994;76:761–775.
   PubMed Web of Science ®Google Scholar
• Chen X, Tukachinsky H, Huang CH, et al. Processing and turnover of the Hedgehog protein in the endoplasmic reticulum. J Cell Biol. 2011;192:825–838.
   PubMed Web of Science ®Google Scholar
• Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14:416–429.
   PubMed Web of Science ®Google Scholar
• Myers BR, Neahring L, Zhang Y, et al. Rapid, direct activity assays for Smoothened reveal Hedgehog pathway regulation by membrane cholesterol and extracellular sodium. Proc Natl Acad Sci USA. 2017;114:E11141–E11150.
   PubMed Web of Science ®Google Scholar
• Ruppert JM, Kinzler KW, Wong AJ, et al. The GLI-Kruppel family of human genes. Mol Cell Biol. 1988;8:3104–3113.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Nishizaki Y, Hui C, et al. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development. 1999;126:3915–3924.
   PubMed Web of Science ®Google Scholar
• Cheng SY, Bishop JM. Suppressor of Fused represses Gli-mediated transcription by recruiting the SAP18-mSin3 corepressor complex. Proc Natl Acad SciUSA. 2002;99:5442–5447.
   PubMed Web of Science ®Google Scholar
• Kogerman P, Grimm T, Kogerman L, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol. 1999;1:312–319.
   PubMed Web of Science ®Google Scholar
• Paces-Fessy M, Boucher D, Petit E, et al. The negative regulator of Gli, Suppressor of fused (Sufu), interacts with SAP18, Galectin3 and other nuclear proteins. The. Biochem J. 2004;378:353–362.
   PubMed Web of Science ®Google Scholar
• Jia J, Amanai K, Wang G, et al. Shaggy/GSK3 antagonizes hedgehog signalling by regulating cubitus interruptus. Nature. 2002;416:548–552.
   PubMed Web of Science ®Google Scholar
• Price MA, Kalderon D. Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell. 2002;108:823–835.
   PubMed Web of Science ®Google Scholar
• Wang B, Li Y. Evidence for the direct involvement of {beta}TrCP in Gli3 protein processing. Proc Natl Acad Sci USA. 2006;103:33–38.
   PubMed Web of Science ®Google Scholar
• Tempe D, Casas M, Karaz S, et al. Multisite protein kinase A and glycogen synthase kinase 3beta phosphorylation leads to Gli3 ubiquitination by SCFbetaTrCP. Mol Cell Biol. 2006;26:4316–4326.
   PubMed Web of Science ®Google Scholar
• Kaesler S, Luscher B, Ruther U. Transcriptional activity of GLI1 is negatively regulated by protein kinase A. Biol Chem 2000;381:545–551.
   PubMed Web of Science ®Google Scholar
• Kenney AM, Rowitch DH. Sonic hedgehog promotes G1 cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol Cell Biol. 2000;20:9055–9067.
   PubMed Web of Science ®Google Scholar
• Kenney AM. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development. 2003;130:15–28.
   PubMed Web of Science ®Google Scholar
• Chen W, Tang T, Eastham-Anderson J, et al. Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci. 2011;108:9589–9594.
   PubMed Web of Science ®Google Scholar
• Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med. 2001;7:706–711.
   PubMed Web of Science ®Google Scholar
• Heiden KB, Williamson AJ, Doscas ME, et al. The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metabol. 2014;99:E2178–E2187.
   PubMed Web of Science ®Google Scholar
• Li X, Deng W, Lobo-Ruppert SM, et al. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by β-catenin. Oncogene. 2007;26:4489–4498.
   PubMed Web of Science ®Google Scholar
• Po A, Ferretti E, Miele E, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. Embo J. 2010;29:2646–2658.
   PubMed Web of Science ®Google Scholar
• Mao J, Maye P, Kogerman P, et al. Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1. J Biol Chem. 2002;277:35156–35161.
   PubMed Web of Science ®Google Scholar
• Castresana JS, Coni S, Antonucci L, et al. Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy. PLoS One. 2013;8:e65718.
   Web of Science ®Google Scholar
• Coni S, Mancuso AB, Di Magno L, et al. Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Sci Rep. 2017;7:44079.
   PubMed Web of Science ®Google Scholar
• Canettieri G, Di Marcotullio L, Greco A, et al. Histone deacetylase and Cullin3–RENKCTD11 ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol. 2010;12:132–142.
   PubMed Web of Science ®Google Scholar
• Stecca B, Ruiz i Altaba A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and Non-HEDGEHOG signals. J Mol Cell Biol. 2010;2:84–95.
   PubMed Web of Science ®Google Scholar
• Brennan D, Chen X, Cheng L, et al. Noncanonical Hedgehog signaling. Vitam Horm. 2012;88:55–72.
   PubMed Web of Science ®Google Scholar
• Seto M, Ohta M, Asaoka Y, et al. Regulation of the hedgehog signaling by the mitogen-activated protein kinase cascade in gastric cancer. Mol Carcinog. 2009;48:703–712.
   PubMed Web of Science ®Google Scholar
• Rajurkar M, De Jesus-Monge WE, Driscoll DR, et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci.. 2012;109:E1038–E1047.
   PubMed Web of Science ®Google Scholar
• Ramaswamy B, Lu Y, Teng K, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;72:5048–5059.
   PubMed Web of Science ®Google Scholar
• Ke Z, Caiping S, Qing Z, et al. Sonic hedgehog–Gli1 signals promote epithelial–mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Med Oncol. 2015;32:368.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhu G, Huang J, et al. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett. 2016;370:313–323.
   PubMed Web of Science ®Google Scholar
• Yoon JW, Lamm M, Iannaccone S, et al. p53 modulates the activity of the GLI1 oncogene through interactions with the shared coactivator TAF9. DNA Repair. 2015;34:9–17.
   PubMed Web of Science ®Google Scholar
• Stecca B, Ruiz i Altaba A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. Embo J. 2009;28:663–676.
   PubMed Web of Science ®Google Scholar
• Chinchilla P, Xiao L, Kazanietz MG, et al. Hedgehog proteins activate pro-angiogenic responses in endothelial cells through non-canonical signaling pathways. Cell Cycle. 2010;9:570–579.
   PubMed Web of Science ®Google Scholar
• Polizio AH, Chinchilla P, Chen X, et al. Heterotrimeric Gi proteins link Hedgehog signaling to activation of Rho small GTPases to promote fibroblast migration. J Biol Chem. 2011;286:19589–19596.
   PubMed Web of Science ®Google Scholar
• Bijlsma MF, Borensztajn KS, Roelink H, et al. Sonic hedgehog induces transcription-independent cytoskeletal rearrangement and migration regulated by arachidonate metabolites. Cell Signal. 2007;19:2596–2604.
   PubMed Web of Science ®Google Scholar
• Yam PT, Langlois SD, Morin S, et al. Sonic hedgehog guides axons through a noncanonical, Src-family-kinase-dependent signaling pathway. Neuron. 2009;62:349–362.
   PubMed Web of Science ®Google Scholar
• Chang H, Li Q, Moraes RC, et al. Activation of Erk by sonic hedgehog independent of canonical hedgehog signalling. Int J Biochem Cell Biol. 2010;42:1462–1471.
   PubMed Web of Science ®Google Scholar
• Belgacem YH, Borodinsky LN. Sonic hedgehog signaling is decoded by calcium spike activity in the developing spinal cord. Proc Natl Acad Sci USA. 2011;108:4482–4487.
   PubMed Web of Science ®Google Scholar
• Mille F, Thibert C, Fombonne J, et al. The patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat Cell Biol. 2009;11:739–746.
   PubMed Web of Science ®Google Scholar
• Thibert C, Teillet MA, Lapointe F, et al. Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. Science. 2003;301:843–846.
   PubMed Web of Science ®Google Scholar
• Adolphe C, Hetherington R, Ellis T, et al. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006;66:2081–2088.
   PubMed Web of Science ®Google Scholar
• Jenkins D, Winyard PJ, Woolf AS. Immunohistochemical analysis of Sonic hedgehog signalling in normal human urinary tract development. J Anatomy. 2007;211:620–629.
   PubMed Web of Science ®Google Scholar
• Jiang X, Yang P, Ma L. Kinase activity-independent regulation of cyclin pathway by GRK2 is essential for zebrafish early development. Proc Natl Acad Sci USA. 2009;106:10183–10188.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Wang JF, Park IW, Groopman JE. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood. 2000;95:2505–2513.
   PubMed Web of Science ®Google Scholar
• Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 2003;63:1969–1974.
   PubMed Web of Science ®Google Scholar
• Rubin JB. Chemokine signaling in cancer: One hump or two? Semin Cancer Biol. 2009;19:116–122.
   PubMed Web of Science ®Google Scholar
• Vila-Coro AJ, Rodriguez-Frade JM, Martin De AA, et al. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 1999;13:1699–1710.
   PubMed Web of Science ®Google Scholar
• Nakata Y. Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine receptors in normal human CD34+ marrow cells. Blood. 2006;107:4234–4239.
   PubMed Web of Science ®Google Scholar
• Ghosh MC, Baatar D, Collins G, et al. Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck. Blood. 2008;113:575–584.
   PubMed Web of Science ®Google Scholar
• Ottoson NC, Pribila JT, Chan ASH, et al. Cutting Edge: T Cell Migration Regulated by CXCR4 Chemokine Receptor Signaling to ZAP-70 Tyrosine Kinase. J Immunol. 2001;167:1857–1861.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Tsai Y-Y, Chen S-Y, et al. Interaction of Zap70 and CXCR4 receptor at lamellipodia that determines the directionality during Jurkat T cells chemotaxis. Mol Immunol. 2017;90:245–254.
   PubMed Web of Science ®Google Scholar
• Markant SL, Esparza LA, Sun J, et al. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Cancer Res. 2013;73:6310–6322.
   PubMed Web of Science ®Google Scholar
• Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488:43–48.
   PubMed Web of Science ®Google Scholar
• Riobo NA, Lu K, Emerson CP Jr. Hedgehog signal transduction: signal integration and cross talk in development and cancer. Cell Cycle. 2006;5:1612–1615.
   PubMed Web of Science ®Google Scholar
• Heussler HS, Suri M. Sonic hedgehog. Mol Pathol: 2003;56:129–131.
   PubMedGoogle Scholar
• Roussel MF, Hatten ME. Cerebellum development and medulloblastoma. Curr Top Develop Biol. 2011;94:235–282.
   PubMed Web of Science ®Google Scholar
• Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. The Oncologist. 2012;17:1090–1099.
   PubMed Web of Science ®Google Scholar
• Xie J, Bartels CM, Barton SW, et al. Targeting hedgehog signaling in cancer: research and clinical developments. OncoTargets Ther. 2013;6:1425–1435.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yu T, Rao Y. Temporal regulation of cerebellar EGL migration through a switch in cellular responsiveness to the meninges. Develop Biol. 2004;267:153–164.
   PubMed Web of Science ®Google Scholar
• Klein RS, Rubin JB, Gibson HD, et al. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development. 2001;128:1971–1981.
   PubMed Web of Science ®Google Scholar
• Ozawa PM, Ariza CB, Ishibashi CM, et al. Role of CXCL12 and CXCR4 in normal cerebellar development and medulloblastoma. Int J Cancer. 2016;138:10–13.
   PubMed Web of Science ®Google Scholar
• Akamandisa MP, Nahta R, Castellino RC. PPM1D/WIP1 in medulloblastoma. Oncoscience. 2016;3:186–187.
   PubMedGoogle Scholar
• Buss MC, Remke M, Lee J, et al. The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. Oncogene. 2015;34:1126–1140.
   PubMed Web of Science ®Google Scholar
• Huang SY, Yang JY. Targeting the Hedgehog pathway in pediatric medulloblastoma. Cancers (Basel). 2015;7:2110–2123.
   PubMed Web of Science ®Google Scholar
• Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381–396.
   PubMed Web of Science ®Google Scholar
• Ward SA, Warrington NM, Taylor S, et al. Reprogramming medulloblastoma-propagating cells by a combined antagonism of sonic Hedgehog and CXCR4. Cancer Res. 2017;77:1416–1426.
   PubMed Web of Science ®Google Scholar
• A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) [Internet]. 2012. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01708174
   Google Scholar
• NCT01125800. A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US). 2010.
   Google Scholar
• NCT00880308. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000 Feb 29. 2009.
   Google Scholar
• NCT01208831. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2016.
   Google Scholar
• Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. JCO. 2015;33:2646–2654.
   PubMed Web of Science ®Google Scholar
• NCT00822458. GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment. ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000 Feb 29. 2009.
   Google Scholar
• Meyers-Needham M, Lewis JA, Gencer S, et al. Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Mol Cancer Ther. 2012;11:1092–1102.
   PubMed Web of Science ®Google Scholar
• Lu X, Peng Y, Wang C, et al. Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors. Eur J Med Chem. 2017;138:384–395.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad SciUSA. 2012;109:7859–7864.
   PubMed Web of Science ®Google Scholar
• Ge X, Milenkovic L, Suyama K, et al. Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma. eLife. 2015;4. DOI: https://doi.org/10.7554/eLife.07068.
   Google Scholar
• Wang J, Peng Y, Liu Y, et al. Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth. BMC Cancer. 2015;15:595.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang N, Li H, et al. Up-Regulation of PAI-1 and down-regulation of uPA are involved in suppression of invasiveness and motility of hepatocellular carcinoma cells by a natural compound berberine. IJMS. 2016;17:577.
   Web of Science ®Google Scholar
• Li B, Fei DL, Flaveny CA, et al. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Res. 2014;74:4811–4821.
   PubMed Web of Science ®Google Scholar
• Rohner A, Spilker ME, Lam JL, et al. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther. 2012;11:57–65.
   PubMed Web of Science ®Google Scholar
• Lu W, Liu Y, Ma H, et al. Design, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine derivatives as potent smoothened antagonists with in vivo activity. ACS Chem Neurosci. 2017;8:1980–1994.
   PubMed Web of Science ®Google Scholar
• Lin Z, Li S, Sheng H, et al. Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis. J Cancer Res Clin Oncol. 2016;142:2469–2478.
   PubMed Web of Science ®Google Scholar
• Lin Z, Sheng H, You C, et al. Inhibition of the CyclinD1 promoter in response to sonic hedgehog signaling pathway transduction is mediated by Gli1. Exp Ther Med. 2017;13:307–314.
   PubMed Web of Science ®Google Scholar
• Bao X, Peng Y, Lu X, et al. Synthesis and evaluation of novel benzylphthalazine derivatives as hedgehog signaling pathway inhibitors. Bioorganic Med Chem Lett. 2016;26:3048–3051.
   PubMed Web of Science ®Google Scholar
• Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100:13513–13518.
   PubMed Web of Science ®Google Scholar
• Yang L, Jackson E, Woerner BM, et al. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007;67:651–658.
   PubMed Web of Science ®Google Scholar
• Van Hout A, D'Huys T, Oeyen M, et al. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One. 2017;12:e0176057.
   PubMed Web of Science ®Google Scholar
• Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49:219–230.
   PubMed Web of Science ®Google Scholar
• Redjal N, Chan JA, Segal RA, et al. CXCR4 Inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12:6765–6771.
   PubMed Web of Science ®Google Scholar
• Jager T, Ocker M, Kiesslich T, et al. Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. Expert Opin Investig Drugs. 2017;26:133–136.
   PubMed Web of Science ®Google Scholar
• Yang L, Xie G, Fan Q, et al. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene. 2010;29:469–481.
   PubMed Web of Science ®Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20:1900–1909.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–1178.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013;19:6305–6312.
   PubMed Web of Science ®Google Scholar
• Khatra H, Bose C, Sinha S. Discovery of hedgehog antagonists for cancer therapy. Curr Med Chem. 2017;24:2033–2058.
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GJP, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572–574.
   PubMed Web of Science ®Google Scholar
• Lauth M, Bergstrom A, Shimokawa T, et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 2007;104:8455–8460.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA. 2010;107:13432–13437.
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121:148–160.
   PubMed Web of Science ®Google Scholar
• Infante P, Mori M, Alfonsi R, et al. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. Embo J. 2015;34:200–217.
   PubMed Web of Science ®Google Scholar
• Infante P, Alfonsi R, Botta B, et al. Targeting GLI factors to inhibit the Hedgehog pathway. Trends in Pharmacol Sci. 2015;36:547–558.
   PubMed Web of Science ®Google Scholar
• Huang L, Walter V, Hayes DN, et al. Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin Cancer Res. 2014;20:1566–1575.
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Kaylani SZ, Edrees N, et al. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. Oncotarget 2014;5:12151–12165.
   PubMed Web of Science ®Google Scholar
• Wang J, Gu S, Huang J, et al. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells. BMC Cancer. 2014;14:768.
   Web of Science ®Google Scholar
• Li J, Cai J, Zhao S, et al. GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment. J Exp Clin Cancer Res. 2016;35:184.
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Masuelli L, De Smaele E, et al. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors. Oncotarget. 2016;7:9250–9270.
   PubMed Web of Science ®Google Scholar
• Wellbrock J, Latuske E, Kohler J, et al. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clin Cancer Res. 2015;21:2388–2398.
   PubMed Web of Science ®Google Scholar
• Di Magno L, Coni S, Di Marcotullio L, et al. Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. Biochimica Et Biophysica Acta. 2015;1856:62–72.
   PubMed Web of Science ®Google Scholar
• D'Amico D, Canettieri G. Translating Hedgehog in cancer: controlling protein synthesis. Trends Mol Med. 2016;22:851–862.
   PubMed Web of Science ®Google Scholar
• Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27:327–341.
   PubMed Web of Science ®Google Scholar
• Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015;9:389–397.
   PubMed Web of Science ®Google Scholar
• Hoch L, Faure H, Roudaut H, et al. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. FASEB J. 2015;29:1817–1829.
   PubMed Web of Science ®Google Scholar
• Atwood Scott X, Sarin Kavita Y, Whitson Ramon J, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27:342–353.
   PubMed Web of Science ®Google Scholar